The Europe Protein A Resin Market would witness market growth of 5.7% CAGR during the forecast period (2022-2028).
Protein A agarose bead is the frequently used matrix in industries or labs amidst different matrices. The agarose beads are interlinked to Protein A resin by amide bond creation. As a result, these beads have a high affinity & capacity for antibodies. Moreover, Protein A agar beads are also opposed to urea, chaotropic agents (like potassium thiocyanate & guanidine hydrochloride), and a wide pH range from 2-11.
Thus, it doesn’t get damaged or break easily even in severe elution conditions, like when detaching bound antibodies. Protein A resin has multiple applications, varying from its usage in biomanufacturing & bioprocessing assays to affinity chromatographic assays, and immunoprecipitation.
Because of its specificity, the resin is selected as a usual method to obtain antibodies in the purification procedure. Recombinant Streptococcal Protein A is the extensively used resin among all the accessible commercial proteins. It is delicate to alkaline situations and, therefore, cannot be utilized with cost-effective & rigorous NaOH and CIP-associated sanitization protocols.
The increasing population and the changes in demography will place constant stress on the UK’s system. It is estimated that approximately 26 million people have long-term health conditions. Government stats state that 63% of adults are overweight or obese. The number of people over 65 is estimated to rise from 18% in 2018 to 23.9% in 2036. With the increasing old aged population and development of well-organized and robust healthcare infrastructure, the market is predicted to grow in the Europe region.
The Germany market dominated the Europe Protein A Resin Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $125.3 million by 2028.The UK market is anticipated to grow at a CAGR of 4.8% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 6.5% during (2022 - 2028).
Based on Product Type, the market is segmented into Agarose-based, Glass/Silica-based and Organic Polymer-based. Based on End Use, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Academic Research Institutes and Others. Based on Type, the market is segmented into Recombinant and Natural. Based on Application, the market is segmented into Antibody Purification and Immunoprecipitation. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Repligen Corporation, PerkinElmer, Inc, Thermo Fisher Scientific, Inc., Merck Millipore (Merck Group), Genscript Biotech Corporation, Agilent Technologies, Inc., Abcam plc, and Novasep Holdings SAS (Azulis Capital).
Protein A agarose bead is the frequently used matrix in industries or labs amidst different matrices. The agarose beads are interlinked to Protein A resin by amide bond creation. As a result, these beads have a high affinity & capacity for antibodies. Moreover, Protein A agar beads are also opposed to urea, chaotropic agents (like potassium thiocyanate & guanidine hydrochloride), and a wide pH range from 2-11.
Thus, it doesn’t get damaged or break easily even in severe elution conditions, like when detaching bound antibodies. Protein A resin has multiple applications, varying from its usage in biomanufacturing & bioprocessing assays to affinity chromatographic assays, and immunoprecipitation.
Because of its specificity, the resin is selected as a usual method to obtain antibodies in the purification procedure. Recombinant Streptococcal Protein A is the extensively used resin among all the accessible commercial proteins. It is delicate to alkaline situations and, therefore, cannot be utilized with cost-effective & rigorous NaOH and CIP-associated sanitization protocols.
The increasing population and the changes in demography will place constant stress on the UK’s system. It is estimated that approximately 26 million people have long-term health conditions. Government stats state that 63% of adults are overweight or obese. The number of people over 65 is estimated to rise from 18% in 2018 to 23.9% in 2036. With the increasing old aged population and development of well-organized and robust healthcare infrastructure, the market is predicted to grow in the Europe region.
The Germany market dominated the Europe Protein A Resin Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $125.3 million by 2028.The UK market is anticipated to grow at a CAGR of 4.8% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 6.5% during (2022 - 2028).
Based on Product Type, the market is segmented into Agarose-based, Glass/Silica-based and Organic Polymer-based. Based on End Use, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Academic Research Institutes and Others. Based on Type, the market is segmented into Recombinant and Natural. Based on Application, the market is segmented into Antibody Purification and Immunoprecipitation. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Repligen Corporation, PerkinElmer, Inc, Thermo Fisher Scientific, Inc., Merck Millipore (Merck Group), Genscript Biotech Corporation, Agilent Technologies, Inc., Abcam plc, and Novasep Holdings SAS (Azulis Capital).
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Agarose-based
- Glass/Silica-based
- Organic Polymer-based
By End Use
- Pharmaceutical & Biopharmaceutical Companies
- Academic Research Institutes
- Others
By Type
- Recombinant
- Natural
By Application
- Antibody Purification
- Immunoprecipitation
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- General Electric (GE) Co. (GE Healthcare)
- Repligen Corporation
- PerkinElmer, Inc
- Thermo Fisher Scientific, Inc
- Merck Millipore (Merck Group)
- Genscript Biotech Corporation
- Agilent Technologies, Inc
- Abcam plc
- Novasep Holdings SAS (Azulis Capital)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Protein A Resin Market, by Product Type
1.4.2 Europe Protein A Resin Market, by End Use
1.4.3 Europe Protein A Resin Market, by Type
1.4.4 Europe Protein A Resin Market, by Application
1.4.5 Europe Protein A Resin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Protein A Resin Market
Chapter 4. Europe Protein A Resin Market by Product Type
4.1 Europe Agarose-based Market by Country
4.2 Europe Glass/Silica-based Market by Country
4.3 Europe Organic Polymer-based Market by Country
Chapter 5. Europe Protein A Resin Market by End-use
5.1 Europe Pharmaceutical & Biopharmaceutical Companies Market by Country
5.2 Europe Academic Research Institutes Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Protein A Resin Market by Type
6.1 Europe Recombinant Market by Country
6.2 Europe Natural Market by Country
Chapter 7. Europe Protein A Resin Market by Application
7.1 Europe Antibody Purification Market by Country
7.2 Europe Immunoprecipitation Market by Country
Chapter 8. Europe Protein A Resin Market by Country
8.1 Germany Protein A Resin Market
8.1.1 Germany Protein A Resin Market by Product Type
8.1.2 Germany Protein A Resin Market by End-use
8.1.3 Germany Protein A Resin Market by Type
8.1.4 Germany Protein A Resin Market by Application
8.2 UK Protein A Resin Market
8.2.1 UK Protein A Resin Market by Product Type
8.2.2 UK Protein A Resin Market by End-use
8.2.3 UK Protein A Resin Market by Type
8.2.4 UK Protein A Resin Market by Application
8.3 France Protein A Resin Market
8.3.1 France Protein A Resin Market by Product Type
8.3.2 France Protein A Resin Market by End-use
8.3.3 France Protein A Resin Market by Type
8.3.4 France Protein A Resin Market by Application
8.4 Russia Protein A Resin Market
8.4.1 Russia Protein A Resin Market by Product Type
8.4.2 Russia Protein A Resin Market by End-use
8.4.3 Russia Protein A Resin Market by Type
8.4.4 Russia Protein A Resin Market by Application
8.5 Spain Protein A Resin Market
8.5.1 Spain Protein A Resin Market by Product Type
8.5.2 Spain Protein A Resin Market by End-use
8.5.3 Spain Protein A Resin Market by Type
8.5.4 Spain Protein A Resin Market by Application
8.6 Italy Protein A Resin Market
8.6.1 Italy Protein A Resin Market by Product Type
8.6.2 Italy Protein A Resin Market by End-use
8.6.3 Italy Protein A Resin Market by Type
8.6.4 Italy Protein A Resin Market by Application
8.7 Rest of Europe Protein A Resin Market
8.7.1 Rest of Europe Protein A Resin Market by Product Type
8.7.2 Rest of Europe Protein A Resin Market by End-use
8.7.3 Rest of Europe Protein A Resin Market by Type
8.7.4 Rest of Europe Protein A Resin Market by Application
Chapter 9. Company Profiles
9.1 General Electric (GE) Co. (GE Healthcare)
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 SWOT Analysis
9.2 Repligen Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Acquisition and Mergers:
9.3 PerkinElmer, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Acquisition and Mergers:
9.4 Thermo Fisher Scientific, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.6 Merck Millipore (Merck Group)
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.7 Genscript Biotech Corporation
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional & Segmental Analysis
9.7.4 Research & Development Expenses
9.8 Agilent Technologies, Inc.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.9 Abcam plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expenses
9.10. Novasep Holdings SAS (Azulis Capital)
9.10.1 Company Overview
Companies Mentioned
- General Electric (GE) Co. (GE Healthcare)
- Repligen Corporation
- PerkinElmer, Inc
- Thermo Fisher Scientific, Inc.
- Merck Millipore (Merck Group)
- Genscript Biotech Corporation
- Agilent Technologies, Inc.
- Abcam plc
- Novasep Holdings SAS (Azulis Capital)
Methodology
LOADING...
